This panel will focus on how patent law affects various industries differently. The pharmaceutical and high-tech industries offer perhaps the most vivid examples of this divergence. The panel will also discuss whether patent law currently is or should be technology specific. Finally, the panel will also explore which institutional actor is in the best position to craft substantive patent law to promote innovation policy. Moderated by Melissa Wasserman.
Debating the ethical and legal limits of re-engineering human biology